Published in Blood on December 01, 1995
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A (1996) 2.15
Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A (2010) 1.78
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia (2011) 1.77
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood (2012) 1.56
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia (2013) 1.54
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia (2009) 1.33
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood (2005) 1.22
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood (2005) 1.19
The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol (2007) 1.09
Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J (2011) 1.03
Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J (2015) 1.01
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol (2000) 0.89
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid (2010) 0.89
In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes. Genes Chromosomes Cancer (2014) 0.86
Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. Biomark Res (2014) 0.85
Molecular aspects of multiple myeloma. Mol Pathol (2002) 0.85
Progress in myeloma stem cells. Am J Blood Res (2011) 0.81
Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol (2016) 0.81
Genetic markers used for risk stratification in multiple myeloma. Genet Res Int (2011) 0.79
Clinical value of new staging systems for multiple myeloma. Cancer Res Treat (2007) 0.79
Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes. Clinics (Sao Paulo) (2011) 0.78
Genomic profiling of plasma cell disorders in a clinical setting: integration of microarray and FISH, after CD138 selection of bone marrow. J Clin Pathol (2013) 0.78
Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian context. Mol Cytogenet (2014) 0.77
The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma. Bone Marrow Res (2014) 0.77
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J (2016) 0.77
Rapid evolving into acute myeloid leukemia in a patient with multiple myeloma and concurrent myelodysplasia after VTD therapy. Int J Clin Exp Med (2015) 0.75
Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity. Appl Clin Genet (2010) 0.75
Carbamazepine and hematological malignancies. Turk J Haematol (2013) 0.75
The Evolution of Prognostic Factors in Multiple Myeloma. Adv Hematol (2017) 0.75
Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells. Rev Bras Hematol Hemoter (2016) 0.75
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J (2017) 0.75
Evaluation of 13q14 status in multiple myeloma by digital single nucleotide polymorphism technology. J Mol Diagn (2009) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Transactivation of a human cytomegalovirus early promoter by gene products from the immediate-early gene IE2 and augmentation by IE1: mutational analysis of the viral proteins. J Virol (1990) 4.01
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 2.60
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia (2007) 2.28
Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet (1995) 2.26
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood (1997) 2.13
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol (2001) 2.10
Primary dexamethasone treatment of multiple myeloma. Blood (1992) 2.02
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med (1987) 1.98
Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood (1988) 1.95
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89
VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol (1990) 1.87
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant (2006) 1.85
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 1.80
The characterization of high-resolution G-banded chromosomes of man. Chromosoma (1978) 1.79
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma (2005) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood (1998) 1.68
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Graft-versus-myeloma effect: proof of principle. Blood (1996) 1.58
Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood (1998) 1.58
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood (1999) 1.57
Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer (1983) 1.54
Expression of interleukin-6 in Castleman's disease. Hum Pathol (1993) 1.53
Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood (1994) 1.52
Identification and expression of a human cytomegalovirus early glycoprotein. J Virol (1989) 1.50
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol (1996) 1.46
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood (1995) 1.45
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol (2001) 1.42
Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet (1984) 1.42
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood (2000) 1.39
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood (1995) 1.39
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia (2012) 1.35
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant (2006) 1.35
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia (2009) 1.33
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood (1986) 1.32
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med (1991) 1.32
High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med (1986) 1.31
Secondary acute myelogenous leukemia following safe exposure to etoposide. J Clin Oncol (1997) 1.31
Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood (1999) 1.30
Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest (1985) 1.29
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood (1989) 1.29
Correlation of DNA distribution abnormalities with cytogenetic findings in human adult leukemia and lymphoma. Cancer Res (1977) 1.27
Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med (1990) 1.26
Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood. Blood (1995) 1.26
Characterization of banding patterns of metaphase-prophase G-banded chromosomes and their use in gene mapping. Cytogenet Cell Genet (1978) 1.26
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia (2008) 1.25
The growth fraction of human myeloma cells. Blood (1981) 1.24
Age is not a prognostic variable with autotransplants for multiple myeloma. Blood (1999) 1.23
Mitochondrial DNA determines androgen dependence in prostate cancer cell lines. Oncogene (2006) 1.23
IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant (2003) 1.22
Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol (1996) 1.22
18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol (2005) 1.19
In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res (1980) 1.19
Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood (1998) 1.19
Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry. Cancer Res (1978) 1.18
Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol (1997) 1.17
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol (1990) 1.16
Ploidy and proliferative characteristics in monoclonal gammopathies. Blood (1982) 1.15
High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood (1987) 1.15